Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
| 0.7826 Delayed Data As of Sep 22 |  +0.0147 / +1.91%Today’s Change | 0.68 Today|||52-Week Range 2.65 | -46.40% Year-to-Date |
Latest ADAP News | Press Releases
No recent news for Adaptimmune Therapeutics PLC.
Today’s Trading
| Previous close | 0.77 |
| Today’s open | 0.76 |
| Day’s range | 0.76 - 0.78 |
| Volume | 31,367 |
| Average volume (3 months) | 758,061 |
| Market cap | $174.4M |
Data as of 3:59pm ET, 09/22/2023
Growth & Valuation
| Earnings growth (last year) | -1.10% |
| Earnings growth (this year) | -185.88% |
| Earnings growth (next 5 years) | +5.60% |
| Revenue growth (last year) | +341.28% |
| P/E ratio | NM |
| Price/Sales | 8.67 |
| Price/Book | 1.55 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| LRMRLarimar Therapeutics... | +0.12 | +2.93% |
| ATRAAtara Biotherapeutic... | 0.00 | 0.00% |
| XOMAXOMA Corp | -0.34 | -2.16% |
| MREOMereo Biopharma Grou... | +0.04 | +3.01% |
Data as of 3:59pm ET, 09/22/2023
Financials
| Next reporting date | November 2, 2023 |
| EPS forecast (this quarter) | -$0.15 |
| Annual revenue (last year) | $27.1M |
| Annual profit (last year) | -$165.4M |
| Net profit margin | -609.46% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Abingdon, Oxfordshire |
Forecasts
